Livers

DODAP is a cationic lipid utilized as the lipid component in liposomes (pKa = 5.59 in TNS binding tests). DODAP is employed for encapsulating siRNA and delivering immunostimulated chemotherapeutic agents both in vitro and in vivo. DODAP holds great promise for research in vaccines and inflammation.

5A2-SC8 is an ionizable amino lipid in lipid nanoparticles (LNPs) that shows high delivery potential and low in vivo toxicity, enabling efficient delivery of small RNAs such as siRNA and miRNA into tumor cells. 5A2-SC8 LNPs can confer a unique delivery fate of RNA within the liver, thereby changing the therapeutic outcomes in cancer models.

306-O12B is an ionizable cationic lipid used to prepare lipid nanoparticles (LNPs) for the delivery of mRNA.

PPZ-A10 is an ionizable cationic lipid. PPZ-A10 preferentially delivers mRNA to liver and spleen immune cells. Pi-LNPs containing PPZ-A10 can effectively deliver mRNA/siRNA to solid tumors.

TT3 is an ionizable lipid-like material and a lipid nanoparticle (LLNs)-based mRNA delivery vector. TT3 exhibits liver and spleen specificity and excellent delivery efficiency.

9A1P9 is a multi-tail ionizable cationic phospholipid. 9A1P9 induces membrane destabilization. 9A1P9 can be used for mRNA delivery t.

DSPE-PEG2000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG2000-R9 can be used for drug delivery.

DSPE-PEG2000-pPB is a PEG compound which composed of DSPE and a cyclic oligopeptide (pPB). pPB has a strong binding affinity with PDGFRβ, which is overexpressed on activated hepatic stellate cells (HSC). DSPE-PEG2000-pPB can be used for drug delivery.

DSG-PEG2000-DHLASLWWGTEL (DSG-PEG2000-Mal-Cys-DHLASLWWGTEL) is a functionalized PEGylated phospholipid conjugate composed of three modular components: distearoylglycerol (DSG) as a lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and the DHLASLWWGTEL peptide as a terminal targeting/functional ligand. DSG-PEG2000-DHLASLWWGTEL can be used in research on targeted drug delivery for hepatocellular carcinoma.

DSG-PEG2000-VIP (DSG-PEG2000-Mal-Cys-HSDAVFTDNYTRLRKQMAVKKYLNSILN) is a functionalized PEGylated phospholipid conjugate composed of three modular components: distearoylglycerol (DSG) as a lipid anchoring group, a 2000 Da polyethylene glycol (PEG) spacer arm, and a VIP peptide as a terminal targeting/functional ligand. DSG-PEG2000-VIP can be used in research such as targeted drug delivery for breast cancer.

DMG-PEG2000-VIP (DMG-PEG2000-Mal-Cys-HSDAVFTDNYTRLRKQMAVKKYLNSILN) is a functionalized PEGylated phospholipid conjugate composed of three modular components: 1,2-dipalmitoyl-sn-glycerol-3-phosphoethanolamine (DMG) as a lipid anchoring group, a 2000 Da polyethylene glycol (PEG) spacer arm, and a VIP peptide as a terminal targeting/functional ligand. DMG-PEG2000-VIP can be used in research such as targeted drug delivery for breast cancer.

DSG-PEG2000-SP94 (DSG-PEG2000-Mal-Cys-SP94) is a functionalized PEGylated phospholipid conjugate composed of three modular components: distearoylglycerol (DSG) as a lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and an SP94 (HY-P11050A) peptide as a terminal targeting/functional ligand. DSG-PEG2000-SP94 can be used in research on targeted drug delivery for hepatocellular carcinoma.

DMG-PEG2000-SP94 (DMG-PEG2000-Mal-Cys-SP94) is a functionalized PEGylated phospholipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as a lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and an SP94 (HY-P11050A) peptide as a terminal targeting/functional ligand. DMG-PEG2000-SP94 can be used in research on targeted drug delivery for hepatocellular carcinoma.

DMG-PEG2000-DHLASLWWGTEL (DMG-PEG2000-Mal-Cys-DHLASLWWGTEL) is a functionalized PEGylated phospholipid conjugate composed of three modular components: dimyristoylglycerol (DMG) as a lipid anchoring group, a polyethylene glycol (PEG) spacer arm with a molecular weight of 2000 Da, and the DHLASLWWGTEL peptide as a terminal targeting/functional ligand. DMG-PEG2000-DHLASLWWGTEL can be used in research on targeted drug delivery for hepatocellular carcinoma.

DSG-PEG5000-Galactose is a conjugate composed of DSG, a PEG chain, and terminal galactose. DSG-PEG5000-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.

DSG-PEG1000-Galactose is a conjugate composed of DSG, a PEG chain, and terminal galactose. DSG-PEG1000-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.

DSG-PEG3400-Galactose is a conjugate composed of DSG, a PEG chain, and terminal galactose. DSG-PEG3400-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.

DSG-PEG1000-Galactose is a conjugate composed of DSG, a PEG chain, and terminal galactose. DSG-PEG1000-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.

DSG-PEG10000-Galactose is a conjugate composed of DSG, a PEG chain, and terminal galactose. DSG-PEG10000-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.

DMG-PEG5000-Galactose is a conjugate composed of dimyristic glycerol (DMG), a PEG chain, and terminal galactose. DMG-PEG5000-Galactose combines the membrane compatibility of phospholipids with the targeted recognition capabilities of galactose, making it suitable for research in biomaterial construction and drug delivery.